Emerging Applications of Triazole Antifungal Drugs
International Journal of Molecular Sciences · 14.01.2026 · 27 (2) · 817
DOI: 10.3390/ijms27020817 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.01.2026. Verfasst von Luiz Ricardo Soldi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia 38405-318, MG, Brazil. Hauptthemen laut MEDLINE: Antifungal Agents, Triazoles, Invasive Fungal Infections, Mycoses. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeicoamento de Pessoal de Nível Superior, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)—Brazil.
Abstract (Originalsprache)
Patients with leukemia are at heightened risk for invasive fungal infections (IFIs) due to profound immunosuppression caused by both the malignancy and its treatment. Chemotherapy-induced neutropenia, mucosal barrier disruption, and impaired innate and adaptive immune responses create a highly permissive environment for opportunistic fungal pathogens. Antifungal prophylaxis, particularly in acute myeloid leukemia (AML), has become a cornerstone in reducing IFI-related morbidity and mortality. This review outlines the immunopathogenic mechanisms underlying susceptibility to IFI and discusses current evidence on the optimal timing and therapeutic strategies for antifungal intervention. The clinical utility of key antifungal agents, namely, posaconazole, isavuconazole, and voriconazole, is critically evaluated. We also examine the potential role of emerging agents such as opelconazole, which enables targeted pulmonary delivery and prolonged epithelial retention, representing a promising approach to IFI prevention. Drug-specific considerations, including pharmacokinetics, drug–drug interactions, toxicity profiles, and cost-effectiveness, are analyzed in the context of clinical decision-making. Finally, we emphasize the importance of tailoring antifungal strategies based on leukemia subtype, immunosuppressive status, and individual patient factors to optimize outcomes and support antifungal stewardship in hematologic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia 38405-318, MG, Brazil.
- Faculty of Odontology, Federal University of Uberlândia, Uberlândia 38405-318, MG, Brazil.
- Tumor Biomarkers and Osteoimmunology Laboratory, Av. Pará, 1720, Block 6T, Room 07, District Umuarama, Uberlândia 38400-000, MG, Brazil.
ORCID-Profile: Luiz Ricardo Soldi, Ana Paula de Lima Oliveira, Marcelo José Barbosa Silva
Förderung
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)—Brazil
Zitieren
APA
Soldi, L. R., Oliveira, A. P. L., & Silva, M. J. B. (2026). Emerging Applications of Triazole Antifungal Drugs. International Journal of Molecular Sciences, 27(2), 817. https://doi.org/10.3390/ijms27020817
Vancouver
Soldi LR, Oliveira APL, Silva MJB. Emerging Applications of Triazole Antifungal Drugs. International Journal of Molecular Sciences. 2026;27(2):817. doi:10.3390/ijms27020817
BibTeX
@article{Soldi2026,
author = {Soldi, Luiz Ricardo and Oliveira, Ana Paula de Lima and Silva, Marcelo José Barbosa},
title = {Emerging Applications of Triazole Antifungal Drugs},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {2},
pages = {817},
doi = {10.3390/ijms27020817}
}
EUVIMED